a reduction in intra-tumoural TAM levels (Gottardis and Jordan, 1988; Osborne et al, 1991 Osborne et al, , 1992 , with stimulation of growth on increasing concentrations in a dose-dependent manner (Gottardis et al, 1989) . In breast cancer patients, TAM and its metabolites accumulate in tumour tissue when compared to serum or plasma (Daniel et al, 1981; Lien et al, 1991a Lien et al, , 1991b , and intra-tumoural levels thus do not necessarily reflect those in the circulation.
Having developed a rapid, sensitive and selective solid-phase extraction (SPE) and a high-performance liquid chromatography (HPLC) separation method for the determination of TAM and its major metabolites in plasma (MacCallum et al, 1996) and tumour tissue, the aim of the present study was to correlate levels in tumour tissue and plasma with response to TAM therapy in a group of breast cancer patients.
MATERIALS AND METHODS
TAM base (z-type isomer), cis-TAM (CIS, e-type isomer) and metabolites 4OH and DMT were generously supplied by Zeneca Pharmaceuticals (Macclesfield, UK) . [N-methyl-3 H]TAM was obtained from Amersham International (Little Chalfont, UK). Standard solutions were prepared in methanol (MeOH) and stored at 4°C. MeOH and acetonitrile (ACN) were of HPLC-reagent grade (Rathburn Chemicals, Walkerburn, UK); triethylamine (TEA) and sodium chloride (NaCl) were obtained from Sigma (Poole, UK) and dimethylsulphoxide (DMSO) was analytical grade (Fisons, Loughborough, UK). Water was deionized and bi-distilled in a milli-U10 water purification system (Millipore, Harrow, UK). Solid-phase extraction was carried out on Bond-elut C 2 3-cm
HPLC
The chromatography systems used are detailed in MacCallum et al (1996 MacCallum et al ( , 1997 . For plasma measurement the mobile phase consisted of 1% TEA (in dH 2 O, pH 8.0) in MeOH (11:89, v/v) , and for tumour measurement of 1% TEA (in dH 2 O, pH 9.0) in MeOH (11:89, v/v) . Mobile phase components were passed through a 0.22 µm filter and degassed prior to use. Elution was isocratic at a flow-rate of 1.2 ml min -1 at ambient room temperature.
Patient data
Samples were obtained from patients treated in the Edinburgh Breast Unit. Plasma and primary tumour tissue was obtained at surgery from 54 post-menopausal, ER-rich (> 20 fmol mg -1 cytosol protein) breast cancer patients treated with tamoxifen for at least 3 months (range 3-86 months). Response at 3 months and at surgery (if > 3 months) was monitored by monthly ultrasound and clinical measurement of the tumour. Patients were classified as responding where tumour volume decreased by at least 25% between initial biopsy and the chosen timepoint (3 months and surgery), whilst non-responders showed either no change (< 25% increase or < 25% decrease in volume) or an increase (> 25%) in tumour volume (Forouhi et al, 1994) . Patients were then categorized according to response of their tumour throughout treatment. Thus, tumours decreasing in size with continual reduction or decreasing then showing no change thereafter were considered to be responders (R-R, n = 25); those initially reducing in size but which later increased in size were considered to have developed acquired resistance to tamoxifen (R-NR, n = 22; minimum length of treatment 4 months); and tumours remaining the same size or increasing in size on treatment were considered to show de novo resistance (NR-NR, n = 6).
Sample preparation
This was carried out as detailed in MacCallum et al (1996 MacCallum et al ( , 1997 . Briefly, 1 ml aliquots of plasma, and 0.5 mg aliquots of tumour tissue (all tissue available was dismembrated and 0.5 mg aliquots resuspended in DMSO), were spiked with radioinert CIS (and 3 H TAM in the case of tumour tissue) in order to monitor extraction efficiency. Aliquots were then applied to an activated solid-phase extraction column, which was washed through with dH 2 O, dH 2 O:MeOH (50:50) and ACN. Elution was with 1 M NaCl: MeOH (5:95, v/v) . Samples were then dried, resuspended and analysed by HPLC. For tumour tissue, an aliquot of the resuspended eluent was placed into scintillant to count 3 H TAM for an additional calculation of recovery.
Analyses were carried out in duplicate in the presence of blank plasma and tumour samples, spiked plasma and tumours samples and standards in MeOH as controls. Multiple analyses were carried out to determine reproducibility. Accuracy (± precision) was 111-168% (± 43-63%) for plasma measurement at 10 ng ml -1 , and 63-94% (± 13-26%) for tumour measurement at 20 ng g -1 . Plasma measurements showed a tendency for overestimation at lower concentrations, with greater accuracy at higher concentrations (98-109% ± 5-10% at 1 µg ml -1 ), although there was still a tendency for overestimation of 40H levels.
Concentrations of plasma and tumour were calculated from the peak areas measured by HPLC (Figure 1) , and normalized to 100% taking into account extraction efficiency and any day-to-day alteration (monitored via spiked samples), and were expressed as ng ml -1 of plasma and ng g -1 of tissue. Extraction efficiency (± between-day variation) was 59-64% (±2.4-14.5%) at 2 ng ml -1 for plasma measurements and 60-64% (±16-20%) at 20 ng g -1 for tumour measurements.
Statistical analysis
Levels of TAM, 4OH and DMT in blood and tumour tissue were calculated as described previously (MacCallum et al, 1996 , and statistical analysis was carried out to determine associations between metabolite levels and: length of time on tamoxifen; response to tamoxifen at 3 months, final surgery and overall; and weight of patient at presentation (where available). In addition, tumour:plasma ratios were correlated with time and response; and the possible effects of tumour cellularity were examined by correlation with ER values.
Analyses on the mean concentrations of each metabolite were carried out using non-parametric tests, as the data were not normally distributed. Tests included Spearman rank, Mann-Whitney, Kruskal-Wallis and Pearson tests, correlation and regression analysis.
RESULTS
Levels of TAM, 4OH or DMT in blood plasma and tumour tissue were correlated with treatment time in both a continuous manner, and additionally using arbitrary time divisions (< 5 months, 5-11 months and > 11 months of treatment) ( Table 1) . Although there was no significant accumulation of plasma or tumour TAM or DMT levels with time, levels of 4OH in tumour tissues showed a tendency to increase with increasing time on TAM (Kruskal-Wallis, P = 0.066), whilst tumours from patients receiving < 5 months of treatment were found to contain significantly less 4OH when compared to those receiving > 11 months of treatment (Mann-Whitney, P = 0.02). Additionally, in those patients showing overall acquired resistance to tamoxifen, there was significant accumulation of 4OH continuously over treatment duration (R-NR, Spearman rank, P = 0.017) ( Figure 2 ). In contrast, plasma concentrations of 4OH were found to be significantly higher in the 5-11 months treatment group, when compared to the other arbitrary groupings (Mann-Whitney, P = 0.04, Table 1 ). All patients were treated with the same dose of TAM (20 mg day -1 ). However, there is evidence from an overlapping study on patients treated at the Edinburgh Breast Unit, that there is a correlation between TAM levels and weight, especially in the upper quartile (Love et al, 1997) . Thus, where available (n = 32), we examined patient weight (kg) at time of presentation in association with TAM and metabolite levels. There were no significant correlations between weight and levels of 4OH or DMT although TAM levels did show a tendency to increase with increasing weight and time in tumours exhibiting acquired resistance (R-NR, regression analysis, r = 0.03). When patients were divided arbitrarily into three groups; < 63, 63-69 and > 69 kg initial weight, again no significant differences were apparent (Table 1) . Further, when weight was taken into account, mean concentrations of TAM, 4OH and DMT in plasma (ng ml -1 kg -1 ) and tumour (ng g -1 kg -1 ) showed no significant differences between the three response groups.
Where levels of TAM, 4OH and DMT in tumour were correlated with response after 3 months of treatment, and at surgery, there were no significant differences between tumours which either responded or did not respond to TAM (Table 2 ). However, similarily grouped plasma levels showed differences between responding and non-responding patients after 3 months of TAM. Plasma levels of 4OH and DMT were significantly higher in nonresponding patients (Mann-Whitney, P = 0.05, P = 0.03). No such differences were seen for TAM after 3 months of treatment, or for any of the three species in plasma taken at surgery.
Patients were additionally grouped according to overall tumour response (Table 3) . Once again, no significant differences were seen in plasma or tumour levels of TAM, 4OH or DMT in relation to response type, the exception being significantly higher levels of DMT in the plasma of the de novo resistant group when compared to the responding group (Mann-Whitney, P = 0.03). Tumour:plasma ratios were calculated to evaluate tumour accumulation of TAM, but once again no significant differences were seen between response groups.
To examine the inter-relationships between metabolite levels, tumour concentrations of each metabolite were plotted against each of the others. On doing this we noted significant associations between TAM and 4OH in de novo resistant tumours, and between TAM and DMT in responding and acquired resistance tumours (Figure 4) . Levels of TAM and metabolites were wide-ranging throughout the group of patients, which may reflect the large heterogeneity of breast cancers, and the presence of areas of non-neoplastic cells within our tissue samples. Whilst we attempted to minimize this effect during our sample preparation, we were unable to correct entirely for differences in tissue cellularity. ER values (fmol mg -1 cytosol protein), were known in 41 samples. No correlations were evident with metabolite levels (mg ml -1 or mg g -1 ) (data not shown). Interestingly, two samples taken from involved lymph nodes were available, in both of which concentrations of TAM, 4OH and DMT had accumulated to very high levels (Table 3) .
Other samples examined included a number of mucoid cancers, in which cases, response to treatment is difficult to ascertain by clinical and ultrasound measurement. No significant differences in concentrations of TAM, 4OH and DMT were noted when comparing the three response groups (Table 3) . Additionally a small number of samples were available from ER-poor patients who had received short-term TAM therapy (Table 3) . Tumour metabolite levels did not differ significantly from the other response groups, however, whilst 4OH plasma levels did not differ greatly in the three main response groupings, levels in ER-poor patient plasmas were significantly lower than all other subgoupings (apart from mucoid tumours) (Mann-Whitney, P = 0.01-0.03). Similarily, levels of DMT in ER-poor patient plasmas were significantly lower than in both responding and de novo resistant patients (Mann-Whitney, P = 0.03, P = 0.0003), whilst TAM levels in this group were significantly less than those in the de novo resistant group (Mann-Whitney, P = 0.01).
DISCUSSION
The aim of this study was to measure levels of TAM, 4OH and DMT in plasma and tumour tissue taken from patients undergoing primary neoadjuvant therapy with TAM, and to correlate these with the response of individual tumours to treatment. After an initial tumour biopsy, patients were treated with TAM for at least 3 months, during which time the response of the remaining tumour was monitored. Thus, we have been able to subdivide patients not only as to whether their tumours exhibited resistance to TAM or not, but also whether this was de novo, or acquired resistance. We hoped to discover if differences in levels of TAM and its major metabolites could account for differences in tumour response. Levels of TAM and metabolites in both plasma and tumour tissue compared well with those previously reported, although there was a tendency for levels of 4OH and DMT to be somewhat higher than those detected by other investigators (Daniel et al, 1979; Robinson et al, 1989; Langan-Fahey et al, 1990; Lim et al, 1993; MacCallum et al, 1997) . There could be several explanations for this: from recovery of spiked plasmas, 4OH as the first metabolite off the HPLC column was seen to be the metabolite most likely to be contaminated with spurious peaks, thus overestimation of plasma levels of all three metabolites, most especially 4OH (as the metabolite present at the lowest concentrations) is a possibility. Alternatively, high levels of this metabolite could reflect differences in patient population (taking into account those patients with responding as well as non-responding tumours); with many patients undergoing long-term TAM therapy, levels could reflect accumulation of 4OH with time, for which there is some evidence with regard to tumour tissue (Table 1 and Results), particularily in RNR patients (Figure 2) .
On statistical analysis, where tumour levels of TAM, 4OH and DMT were correlated with response to therapy, whether at 3 months, at the time of final surgery or overall, there were no significant differences which would account for the development of resistance to TAM, although differences in the mean and median levels of each metabolite did exist. However, the range of values in each group was wide (see Tables 1-3) , thereby nullifying the statistical strength of these differences. Whilst this is a likely reflection of the reproducibility of our assay (as constrained by tissue availability), it may also reflect the heterogeneity of breast tumours, and could relate to tumour cellularity. Whilst we attempted to minimize the effects of heterogeneity, we were unable to correct for cellularity within our sample group. It is interesting to note that high levels of metabolites were found in two lymph node metastases sampled (Table 3) , as these are highly cellular.
Investigations on inter-relationships between metabolites carried out by plotting the tumour concentration of one against the others show some interesting data (Figure 4 .). Concentrations of TAM and 4OH were significantly associated in de novo resistant tumours, suggesting that levels of TAM in these tumours could indicate similar trends in levels of 4OH, whilst responding and acquired resistance tumours showed significant associations between TAM and DMT levels. These results could indicate fundamental differences in the metabolism of TAM within the different response groups.
On analysis of plasma levels, some significant differences were noted, particularily after 3 months of TAM treatment. At this time, plasma levels of both 4OH and DMT in responding patients were found to be significantly lower than those in non-responding patients (Table 2) , whilst plasma DMT levels were significantly higher in de novo resistant patients when compared to responding patients (Table 3 ). These differences could indicate increased metabolism of TAM in non-responding patients, or increased uptake of these metabolites into tumour tissues in responding patients. Certainly, there is evidence for accumulation of 4OH in tumour tissues of the acquired resistance group with increasing treatment time.
Our results are contrary to the decreased accumulation of tamoxifen found in tumours showing acquired resistance, which has been reported by several investigators (Osborne et al, 1987 (Osborne et al, , 1991 (Osborne et al, , 1992 Johnstone et al, 1993) . There could be several reasons for this. We mention previously that differences in the population of patients involved in the study, with the inclusion of both responding and non-responding patients, may have had an effect, and we have not involved ER-poor patients in the whole analysis as others have. The inclusion in the present study of a substantial number of patients on long-term TAM therapy may confound, hiding the predominantly short-term effects reported on previously.
On analysis of a small number of ER-poor patients (n = 8, 1-3 months TAM), we found significantly lower plasma levels of each metabolite when compared to certain of the other response groups (Table 3 and Results). This could be indicative of the short TAM treatment given to these patients, although there is no such evidence for such low levels of plasma in ER-rich patients receiving equally brief treatment (Table 1, < 5 months treatment) . Indeed, it is thought that steady-state levels of the drug are reached within 1 month of treatment (Langhan-Fahey et al, 1990; Robinson and Jordan, 1994) . Although ER-poor tumour levels were seen to be compatable with the other groups, low levels in plasma may indicate differences in uptake or metabolism of TAM in these patients from the commencement of treatment. Certain markers of tumour growth can be examined and proven predictive of response prior to the achievement of steady-state TAM levels (Cameron et al, 1997) . Early differences in levels of, or accumulation of, TAM and metabolites may yet prove to be of importance.
Where tumour levels were evaluated against overall response, no significant differences in uptake were noted which would account for differences in response. However, where length of treatment was also considered, tumour tissue 4OH levels accumulated significantly over time (Table 1 and Results), especially in the subset of tumours showing acquired resistance (Figure 2 ). As these patients had undergone prolonged TAM therapy, this could indicate a slow change within the tumour, such as clonal expansion of resistant cells, or a change in tumour cell adaptive processes thereby causing a switch from response to resistance in the presence of a highly potent anti-oestrogen (100-1000 times stronger than TAM).
In a previous study involving an overlapping group of patients treated at the Edinburgh Breast Unit, there was evidence of a correlation between TAM levels and weight (Love et al, 1997) , although no previous correlations between TAM or DMT levels and obesity have been found (Langhan-Fahey et al, 1990 ). Analysis of the data for patients whose weight at presentation was known, and for whom a ratio of tumour or plasma concentration kg -1 was produced, showed no significant differences between response groups.
In this study we did not set out to obtain evidence for tamoxifenstimulated tumour growth, such as measuring the amount of metabolite E (Osborne, 1995) , as we were looking for differences in metabolism or drug accumulation which could account for resistance to therapy. From our study, it would appear that knowledge of tumour levels of TAM, 4OH and DMT does not correlate with response to TAM therapy. In certain subgroups of our study group, both plasma and tumour levels may indeed have relevance to response, if taken in combination with other factors such as length of treatment.
